

07 Feb 2019 | News

QUOTED. Feb. 7, 2019. Dirk Westermann.

by

New trial results raise some questions about the effectiveness of Abiomed's *Impella* heart pump. The data underscore the need for randomized studies to help identify the best treatment approach for patients with acute myocardial infarction complicated by cardiogenic shock, trial investigator and cardiologist Dirk Westermann says.

“We don't have a lot of evidence, but we need to run trials as long as we can to find better evidence and then we can treat our patients with more certainty that we're really helping them.”
– Dirk Westermann, STOP SHOCK trial investigator, University Heart Center (Hamburg, Germany)

- Find out more: [Impella Fails To Improve Mortality In Non-Randomized STOP-SHOCK](#)

[Click here](#) for a free trial of *Medtech Insight*